Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2024-10-15 | 2024-10-15 |
| Drug Identification Number | 02024284 | 02024284 |
| Brand name | NOVOLIN GE TORONTO PENFILL | NOVOLIN GE TORONTO PENFILL |
| Common or Proper name | NOVOLIN GE TORONTO PENFILL | NOVOLIN GE TORONTO PENFILL |
| Company Name | NOVO NORDISK CANADA INC | NOVO NORDISK CANADA INC |
| Ingredients | INSULIN INJECTION HUMAN BIOSYNTHETIC | INSULIN INJECTION HUMAN BIOSYNTHETIC |
| Strength(s) | 100UNIT | 100UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 5 | 5 |
| ATC code | A10AB | A10AB |
| ATC description | INSULINS AND ANALOGUES | INSULINS AND ANALOGUES |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2025-12-31 | 2025-12-31 |
| Actual discontinuation date | ||
| Remaining supply date | 2025-12-31 | 2025-12-31 |
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |